United States Federal Circuit
GLAXO WELLCOME, INC. v. IMPAX LABS., INC., 03-1013
Because plaintiff cannot prove infringement literally or under the doctrine of equivalents, summary judgment was appropriate. There is ample evidence to find that HPC, the asserted equivalent, was a foreseeable sustained release agent for bupropion.
Appellate Information
- Decided 01/29/2004
- Published 01/29/2004
Judges
- RADER, Circuit Judge., Before RADER, Circuit Judge, PLAGER, Senior Circuit Judge, and GAJARSA, Circuit Judge.
Court
- United States Federal Circuit
Counsel
- For Appellant:
- Stephen B. Judlowe, Morgan Lewis & Bockius LLP, of New York, NY, argued for plaintiff-appellant. With him on the brief were Dennis J. Mondolino, Jason A. Lief, and Timothy P. Heaton.
- For Appellees:
- Steven J. Lee, Kenyon & Kenyon, of New York, NY, argued for defendant-appellee.